About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

By: via Business Wire

Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.

The report was authored by an external group of U.S. investigators involved in the treatment of these patients with narsoplimab provided under Omeros’ compassionate use program. It will be featured as a poster presentation at the 2024 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 21-24, 2024 in San Antonio, Texas.

The poster will be presented by Lindsay Adkins, MSN, FNP-BC, BMTCN, of the Sarah Cannon Transplant and Cellular Therapy Program, Nashville, Tennessee. Details of the presentation are as follows:

Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (Poster #186)

Poster Session: Acute Regimen-Related Toxicity and Supportive Care

Date: Thursday, February 22, 2024

Presentation Time: 6:45 - 7:45 p.m. CST

Location: Exhibit Hall 4A

The presentation abstract is available now on the Tandem Meetings website at the following link:

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23952

The poster is expected to be made available on Omeros’ website at www.investor.omeros.com shortly after the meeting presentation.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a BLA pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead inhibitor of phosphodiesterase 7 OMS527 is in clinical development for the treatment of cocaine use disorder and is also being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “expect,” “intend,” and similar expressions and variations thereof. Forward-looking statements, including statements regarding Omeros’ investigational drug candidates, anticipated next steps in relation to the BLA for narsoplimab or in relation to other development programs are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unanticipated or unexpected outcomes of regulatory processes in relevant jurisdictions, unproven preclinical and clinical development activities, the Company’s financial condition and results of operations, regulatory processes and oversight, challenges associated with manufacture or supply of our investigational or clinical products, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2023. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

More News

View More
Datavault AI: The New AI Contender Backed by Big Funding
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
CoreWeave: Why the New King of AI Infrastructure Has Room to Run
Via MarketBeat
Topics Artificial Intelligence
Tickers CORZ CRWV META NVDA
Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Via MarketBeat
Topics Artificial Intelligence World Trade
Tickers FDX PFE UPS VZ
Etsy Partners With OpenAI—What It Means for Investors Now
Via MarketBeat
Topics Artificial Intelligence
Tickers ETSY
3 Solid Consumer Brands Offering Stability in Volatile Markets
Via MarketBeat
Topics Economy
Tickers AOUT JAKK KO PG SN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.